Vnitřní lékařství 4/2020

PŘEHLEDOVÉ ČLÁNKY Krvácení do GIT při portální hypertenzi E16 | VNITŘNÍ LÉKAŘSTVÍ / Vnitř Lék 2020; 66(2): e7–e16  /  www.casopisvnitrnilekarstvi.cz 57. Hamdy N, Demerdash E. New therapeutic aspect for carvedilol: antifibrotic effects of carvedilol in chronic carbon tetrachloride-induced liver damage. Toxicol Appl Pharma‑ col 2012; 261: 292–299. 58. Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004; 292: 2227–2236. 59. Lo GH, Chen WC, Wang HM, et al. Randomized controlled trial of carvedilol versus na‑ dolol plus isosorbide mononitrate for the prevention of variceal rebleeding. J Gastroen‑ tol Hepatol 2012; 27: 1681–1687. 60. Vlachogiannakos J, Goulis J, Patch D, et al. Review article: primary prophylaxis for portal hypertensive bleeding in cirrhosis. Aliment Pharmacol Ther 2000; 14: 851–860. 61. Groszmann RJ, Garcia-Tsao G, Bosch J, et al. Beta-blockers to prevent gastroesophage‑ al varices in patients with cirrhosis. N Engl J Med 2005; 353: 2254–2261. 62. Imperiale T, Chalasani N. A meta-analysis of endoscopic variceal ligation for primary prophylaxis of esophageal variceal bleeding. Hepatology 2001; 33: 802–807. 63. Grace N, Lo GH, Nevens F, et al. Preventing rebleeding in 2010. In: De Franchis R et al. Portal Hypertension V: Proceedings of the Fifth Baveno International Consensus Workshop, 5th Edition. Wiley-Blackwell press. London 2044: 121–131. 64. Monescillo A, Martínez-Lagares F, Ruiz-del-Arbol L, et al. Influence of portal hyperten‑ sion and its early decompression by TIPS placement on the outcome of variceal bleeding. Hepatology 2004; 40: 793–801. 65. Garcia-Pagán JC, Caca K, Bureau C, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med 2010; 362: 2370–2379. 66. Garcia-Pagán JC, Di Pascoli M, Caca K et al. Use of early-TIPS for high-risk variceal blee‑ ding: results of a post-RCT surveillance study. J Hepatol. 2013; 58: 45–50. 67. Lo GH, Lai KW, Cheng JS, et al. Endoscopic variceal ligation plus nadolol and sucralfa‑ te compared with ligation alone for the prevention of variceal rebleeding: a prospective, randomised trial. Hepatology 2000; 32: 462–465. 68. De la Pena J, Brullet E, Sanchez-Hernández E, et al. Variceal ligation plus nadolol com‑ pared with ligation for prophyla for prophylaxis of variceal rebleeding: a multicenter trial. Hepatology 2005; 41: 572–578. 69. Sersté T, Francoz C, Durand F, et al. Beta-blockers cause paracentesis-induced circu‑ latory dysfunction in patients with cirrhosis and refraktory ascites: a cross-over study. J Hepatol 2011; 55: 794–799. 70. Sersté T, Melot C, Francoz C, et al. Deleterious effect of beta-blockers on survival in pa‑ tients with cirrhosis and refractory ascites. Hepatology 2010; 52: 1017–1022. 71. Krag A, Wiest R, Albillos A, et al. The window hypothesis: haemodynamic and non-ha‑ emodynamic effect of beta-blockers improve survival of patients with cirrhosis during a window in the disease. Gut 2012; 61: 967–969. 72. Ge PS, Runyon BA. The changing role of beta-blocker therapy in patients with cirrho‑ sis. J Hepatol 2014; 60: 643–653. 73. Garcia-Tsao J, et al. AASLD Practice Guidelines. Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis. Hepatology 2007; 46: 922–938. 74. Ryan BM, Stockbrugger RW, Ryan JM. A Pathophy¬siologic, Gastroenterologic and radiologic Approach to the Managament of gastric Varices. Gastroenterology 2004; 126: 1175–1189. 75. Sarin SK, Lahoti D, Saxena SP, et al. Prevalence, classification and natural history of gas‑ tric varices: a long-term follow-up study in 568 portal hypertension patients. Hepatolo‑ gy 1992; 16: 1343–1349. 76. Sarin SK, Kumar A. Gastric varices: profile, classification and management. Am J Gas‑ troenterol 1989; 84: 1244–1249. 77. Lo Gh, Lai Kh, Cheng JS, et al. A prospective randomized trial of butyl cyanoacrylate injection versus band ligation in the management of bleeding gastric varices. Hepato‑ logy 2001; 33: 1060–1064. 78. Tan PC, Hou MC, Lin HC, et al. A randomized trial of endoscopic treatment of acute gastric variceal haemorrhage: N-butyl-2-cyanoacrylate injection versus band ligation. He‑ patology 2006; 43: 690–697. 79. Tripathi D, Therapondos G, Jackson E, et al. The role of the transjugular intrahepatic portosystemic stent shunt (TIPSS) in the management of bleeding gastric varices: clini‑ cal and haemodynamic correlations. Gut 2002; 51: 270–274. Víte, že listovačky časopisu Klinická farmakologie a farmacie jsou volně dostupné on-line? Mohou být přínosné i pro vás… V posledních číslech najdete tato hlavní témata: Farmakoterapie v zubním lékařství (1/2020) Farmakoterapie v těhotenství a při kojení (4/2019) Nežádoucí účinky léčiv (3/2019) ... a mnoho článků z jiných oblastí medicíny a farmacie www. klinickafarmakologie.cz